The Future of Neurological Studies During COVID-19
November 30, 2020 04:30pm
By Contemporary Clinic Editorial Staff
The International Congress on the Future of Neurology will take place this Fall in New York City, converging experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
The 1st annual
will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.
The Congress, which will take place at the InterContinental New York Times Square, will be chaired by Stephen D. Silberstein, MD, professor of neurology and director of the Jefferson Headache Center in Philadelphia, and will feature programming highly relevant to physicians and other heathcare providers who treat neurological disorders.
Sessions focused on dementia and Alzheimer disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, stroke, and sleep disorders will be led by leaders in the field, where the latest data and best practices will be discussed to better inform clinical decision-making.
Karl Doghramji, MD, professor of psychiatry, neurology, and medicine at Thomas Jefferson University, Medical Director, Jefferson Sleep Disorders Center, and Program Director, Fellowship in Sleep Medicine, will moderate the sleep disorders session, titled "Beyond Counting Sheep: Effective Therapies for Sleep Disorders," where experts in the field will discuss new therapeutic approaches for insomnia, how to best manage narcolepsy and risk for therapeutic abuse, as well as navigating the physiologic and psychologic crossroads at play in excessive daytime sleepiness and obstructive sleep apnea.
In an interview with
, Doghramji discussed some of the central issues currently at play in sleep disorder medicine.
Disturbed sleep is associated with a myriad of impairments. It enhances the risk of future mood disorders, contributes to cognitive impairments, enhances the risk of cardiometabolic disorders, and even shortens lifespan. Sleep disorders also enhance the risk of stroke, and contribute to repeat stroke. It is critical, therefore, that neurologists develop a strategy to identify and manage sleep disorders in clinical settings.
Hypnotic agents are being developed that are not only effective for the management of insomnia, but are also safer than those utilized decades ago, particularly in the realm of daytime residual effects and respiratory compromise. Whereas the older agents were primarily GABA receptor agonists, more recently introduced agents antagonize the orexin receptor, thus muting the arousal drive, which is thought to be exaggerated in insomnia.
Some of the main challenges faced when trying to incorporate nonpharmaceutical treatments like CBT-I are a shortage of properly trained therapists, third party payer support, and time limitations. Given that CBT-I is indicated as a first-line treatment for insomnia, it is imperitive that the healthcare community works harder to better prepare for and provide these therapies to patients, and work closely with payers to ensure access to this treatment modality.
This article first appeared in Neurology Live.